Jason Meyenburg, Gemini CEO
A year into SPAC merger, Gemini restructures pipeline with 20% of staff, leadership on the chopping block
Gemini Therapeutics jumped to Nasdaq in a SPAC deal about a year ago, but on Tuesday announced a significant change in direction.
The biotech will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
